<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>MDV1 - Future Health &#187; news</title>
	<atom:link href="http://www.mdv1.com/category/news/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.mdv1.com</link>
	<description>Future Health</description>
	<lastBuildDate>Wed, 01 Feb 2012 19:19:33 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	
		<item>
		<title>Genetically Modified &#8216;Serial Killer&#8217; T-Cells Obliterate Tumors in Leukemia Patients</title>
		<link>http://www.mdv1.com/2011/08/genetically-modified-serial-killer-t-cells-obliterate-tumors-in-leukemia-patients/</link>
		<comments>http://www.mdv1.com/2011/08/genetically-modified-serial-killer-t-cells-obliterate-tumors-in-leukemia-patients/#comments</comments>
		<pubDate>Thu, 11 Aug 2011 15:46:00 +0000</pubDate>
		<dc:creator>Jose</dc:creator>
				<category><![CDATA[news]]></category>
		<category><![CDATA[cancer cure]]></category>
		<category><![CDATA[doctorS]]></category>
		<category><![CDATA[Leukemia]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[t-cells]]></category>

		<guid isPermaLink="false">http://www.mdv1.com/2011/08/genetically-modified-serial-killer-t-cells-obliterate-tumors-in-leukemia-patients/</guid>
		<description><![CDATA[ScienceDaily (Aug. 10, 2011) — In a cancer treatment breakthrough 20 years in the making, researchers from the University of Pennsylvania&#8217;s Abramson Cancer Center and Perelman School of Medicine have shown sustained remissions of up to a year among a small group of advanced chronic lymphocytic leukemia (CLL) patients treated with genetically engineered versions of [...]]]></description>
		<wfw:commentRss>http://www.mdv1.com/2011/08/genetically-modified-serial-killer-t-cells-obliterate-tumors-in-leukemia-patients/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA revokes Avastin approval for breast cancer.</title>
		<link>http://www.mdv1.com/2010/12/fda-revokes-avastin-approval-for-breast-cancer/</link>
		<comments>http://www.mdv1.com/2010/12/fda-revokes-avastin-approval-for-breast-cancer/#comments</comments>
		<pubDate>Fri, 17 Dec 2010 20:50:57 +0000</pubDate>
		<dc:creator>jbolanos</dc:creator>
				<category><![CDATA[news]]></category>

		<guid isPermaLink="false">http://www.mdv1.com/?p=366</guid>
		<description><![CDATA[WASHINGTON (AFP) The US Food and Drug Administration said Thursday that Avastin is not an effective treatment for breast cancer and said it would take steps to revoke market approval and change the drug&#8217;s label. Acting on the advice of an expert panel earlier this year, the FDA said the drug, also known as bevacizumab, carries risks such as severehigh blood pressure and [...]]]></description>
		<wfw:commentRss>http://www.mdv1.com/2010/12/fda-revokes-avastin-approval-for-breast-cancer/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>FDA Medical Device Regs Updated</title>
		<link>http://www.mdv1.com/2010/08/fda-medical-device-regs-updated/</link>
		<comments>http://www.mdv1.com/2010/08/fda-medical-device-regs-updated/#comments</comments>
		<pubDate>Wed, 04 Aug 2010 19:54:45 +0000</pubDate>
		<dc:creator>Jose</dc:creator>
				<category><![CDATA[blog]]></category>
		<category><![CDATA[news]]></category>
		<category><![CDATA[medical Sevice]]></category>
		<category><![CDATA[surgery]]></category>

		<guid isPermaLink="false">http://www.mdv1.com/?p=323</guid>
		<description><![CDATA[Medtronic, Stryker, J&#38;J Face New U.S. Rules for Medical Device Approvals By David Olmos and Sophia Yan &#8211; Aug 3, 2010 9:01 PM PT Medical device makers Medtronic Inc., Johnson &#38; Johnson and Stryker Corp. face new safety rules under a revamped program laid out by U.S. regulators that may help speed approval of products [...]]]></description>
		<wfw:commentRss>http://www.mdv1.com/2010/08/fda-medical-device-regs-updated/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Parma hospital part of settlement in heart device kickback scheme</title>
		<link>http://www.mdv1.com/2010/06/parma-hospital-part-of-settlement-in-heart-device-kickback-scheme/</link>
		<comments>http://www.mdv1.com/2010/06/parma-hospital-part-of-settlement-in-heart-device-kickback-scheme/#comments</comments>
		<pubDate>Sat, 05 Jun 2010 19:24:19 +0000</pubDate>
		<dc:creator>Jose</dc:creator>
				<category><![CDATA[news]]></category>
		<category><![CDATA[kick back]]></category>
		<category><![CDATA[St Jude]]></category>
		<category><![CDATA[whistle blower]]></category>

		<guid isPermaLink="false">http://www.mdv1.com/?p=180</guid>
		<description><![CDATA[By Peter Krouse, The Plain Dealer June 04, 2010, 11:39AM PARMA, Ohio &#8212; Parma Community General Hospital must pay part of a $3.9 million settlement that resolves civil allegations that St. Jude Medical Inc. paid illegal kickbacks to two hospitals to secure heart-device business, the U.S. Justice Department announced Friday. The kickbacks represented improper rebates [...]]]></description>
		<wfw:commentRss>http://www.mdv1.com/2010/06/parma-hospital-part-of-settlement-in-heart-device-kickback-scheme/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>New Technology for Fibroid Ablation.</title>
		<link>http://www.mdv1.com/2010/01/new-technology-for-fibroid-ablation/</link>
		<comments>http://www.mdv1.com/2010/01/new-technology-for-fibroid-ablation/#comments</comments>
		<pubDate>Wed, 20 Jan 2010 05:31:58 +0000</pubDate>
		<dc:creator>Jose</dc:creator>
				<category><![CDATA[news]]></category>

		<guid isPermaLink="false">http://design.mdv1.com/?p=48</guid>
		<description><![CDATA[News from the Wall Street Journal on a novel new minimally invasive device  that treats fibroids in women. Of all the pains and indignities the female body suffers, some of the most common are uterine fibroids—benign tissue growths in the womb. It&#8217;s estimated that as many as 70% of women develop them at some point. [...]]]></description>
		<wfw:commentRss>http://www.mdv1.com/2010/01/new-technology-for-fibroid-ablation/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
	</channel>
</rss>

